Miguel Forte

President Elect • ISCT

Miguel Forte is CEO of Bone Therapeutics, a Professor at Lisbon University and Board of Directors an Executive Committee member for ARM and a Board Member for Essenscia-Wallonie.

Miguel Forte assumed his role as President-Elect of ISCT in May 2022. Previously, he was Chief Commercialization Officer and Chair of the ISCT Commercialization Committee (2014-2020) leading the expansion of the industrial community, strengthening the Committee to better represent the industrial translational objectives and needs of society membership.

Previously, as CEO of Zelluna Immunotherapy (2017-2019), he established the corporate structure, built the team and launched the strategy for solid tumours allogeneic C&GT. From 2010-2017 Miguel was CMO/COO of TxCell, establishing and leading the professional C&GT product translation development for autoimmune diseases and also participating in the company IPO and several successful raises.

Holds an M.D. and Specialist in Infectious Diseases from the Faculty of Medicine, University of Lisbon, a PhD in Immunology, University of Birmingham, and a certificate in Health Technologies Economics, Stockholm School of Economics. He is a Fellow of the Faculty of Pharmaceutical Medicine of the RCP in the UK.

Also speaking

Dirk Schmitt

Sr. Medical Director Medical Affairs • Taysha Gene Therapies

Antonin de Fougerolles

CEO • Evox Therapeutics

Lars Nieba

CEO and Board Member • Engimmune Therapeutics AG

Event Info


Event Brochure

Take a look at the 2023 Event Brochure for Advanced Therapies Europe.

Download the 2023 Speaker List

Download the 2023 Speaker List for Advanced Therapies Europe here.